Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/47478
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective |
Author: | Delea, T. El-Ouagari, K. Karnon, J. Sofrygin, O. |
Citation: | Breast Cancer Research and Treatment, 2008; 108(3):375-387 |
Publisher: | Kluwer Academic Publ |
Issue Date: | 2008 |
ISSN: | 0167-6806 1573-7217 |
Statement of Responsibility: | Thomas E. Delea, Khalid El-Ouagari, Jonathan Karnon and Oleg Sofrygin |
Abstract: | Background In the primary core analysis of BIG 1–98, a randomized, double-blind trial comparing 5 years of initial adjuvant therapy with letrozole versus tamoxifen in postmenopausal women with hormone receptor-positive (HR+) early breast cancer, letrozole significantly improved disease-free survival by 19% and reduced the risk of breast cancer recurrence by 28% and distant recurrence by 27%. Methods A Markov model was used to estimate the incremental cost per quality-adjusted life year (QALY) gained with 5 years of initial adjuvant therapy with letrozole versus tamoxifen from a Canadian healthcare system perspective. Probabilities of recurrence and side effects for tamoxifen were based on published results of BIG 1–98 and other published population-based studies. Corresponding probabilities for letrozole were calculated by multiplying probabilities for tamoxifen by estimated relative risks for letrozole versus tamoxifen from BIG 1–98. Other probabilities, costs of breast-cancer care and treatment of side effects, and health-state utilities were obtained from published studies. Costs and QALYs were estimated over the lifetime of a cohort of postmenopausal women with HR+ early breast cancer, aged 60 years at initiation of therapy, and discounted at 5% annually. Results Compared with tamoxifen, letrozole yields an additional 0.368 life-years (12.453 vs. 12.086) and 0.343 QALYs (11.582 vs. 11.239). These benefits are obtained at an additional cost of $Can 8,110 ($Can 30,819 vs. $Can 22,709). Cost per QALY gained for letrozole versus tamoxifen is $Can 23,662 (95% CI $Can 15,667–$Can 52,014). Conclusion In postmenopausal women with HR+ early breast cancer, initial adjuvant treatment with letrozole is cost-effective from the Canadian healthcare system perspective. |
Keywords: | Adjuvant therapy Breast cancer Cost-effectiveness Letrozole Tamoxifen |
Description: | The original publication can be found at www.springerlink.com |
Provenance: | Published online: 26 July 2007 |
DOI: | 10.1007/s10549-007-9607-7 |
Published version: | http://www.springerlink.com/content/r807673286r4j409/ |
Appears in Collections: | Aurora harvest Public Health publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.